Fig. 6: Ability of MYC and NME2 to predict Enzalutamide-response outperforms known markers of PCa progression and treatment response. | Nature Communications

Fig. 6: Ability of MYC and NME2 to predict Enzalutamide-response outperforms known markers of PCa progression and treatment response.

From: Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC

Fig. 6

Comparison of MYC and NME2 ability to predict response to Enzalutamide in Abida et al. cohort to known markers of PCa aggressiveness, including (a) transcriptomic and (b) genomic markers. Comparison of MYC and NME2 ability to predict response to Enzalutamide in Abida et al. cohort to known markers of response to ADT and ARSIs including (c) transcriptomic and (d) genomic markers. Comparison of MYC and NME2 ability to predict response to Enzalutamide in Abida et al. cohort to known markers of Enzalutamide-response, including (e) transcriptomic and (f) genomic markers. Two-tailed Welch t-test was utilized to calculate p values to estimate the difference in expression levels (red corresponds to over-expression and blue to under-expression) between high-MYC and high-NME2 group and the rest of the patients for transcriptomic markers in (a, c, e). Two-tailed Fisher-exact test was utilized to calculate p values to estimate the difference in the frequency/occurrence of any genomic alterations between high-MYC and high-NME2 group and the rest of the patients for genomic markers in (b, d, f).

Back to article page